GSK sets out new transparency policy12th October 2012
Britain’s biggest drug manufacturer GlaxoSmithKline has unveiled a new transparency policy under which data from clinical trials will be made more widely available.
The decision to share information from its studies comes three months after GSK was fined $3bn (£1.9bn) for fraud related to concealing safety issues. Chief executive Sir Andrew Witty explained the company will set up an independent panel of experts to review and approve requests from researchers to access the data in a move that is a "first" for a pharmaceutical company.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: GSK sets out new transparency policy
Author: Mark Nicholls
Article Id: 22935
Date Added: 12th Oct 2012